At the 2024 Annual Meeting on September 3, Allarity Therapeutics' stockholders approved multiple significant corporate actions. The company will implement a 1-for-30 reverse stock split effective September 11, 2024, with fractional shares being rounded up to the next whole number. The stock will continue trading under the symbol "ALLR" on Nasdaq with a new CUSIP number.Stockholders also approved reducing the total authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, the company's 2021 Equity Incentive Plan was amended to increase the authorized shares from 2.17 million to 10.59 million.Other approved measures included the election of two Class II directors, ratification of Wolf & Company as the independent auditor, and an amendment to limit certain officers' liability under Delaware law. All seven proposals presented at the meeting received sufficient stockholder approval.

At the 2024 Annual Meeting on September 3, Allarity Therapeutics' stockholders approved multiple significant corporate actions. The company will implement a 1-for-30 reverse stock split effective September 11, 2024, with fractional shares being rounded up to the next whole number. The stock will continue trading under the symbol "ALLR" on Nasdaq with a new CUSIP number.Stockholders also approved reducing the total authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, the company's 2021 Equity Incentive Plan was amended to increase the authorized shares from 2.17 million to 10.59 million.Other approved measures included the election of two Class II directors, ratification of Wolf & Company as the independent auditor, and an amendment to limit certain officers' liability under Delaware law. All seven proposals presented at the meeting received sufficient stockholder approval.